Changes in severity of 2009 pandemic A/H1N1 influenza in England: a Bayesian evidence synthesis

Objective To assess the impact of the 2009 A/H1N1 influenza pandemic in England during the two waves of activity up to end of February 2010 by estimating the probabilities of cases leading to severe events and the proportion of the population infected. Design A Bayesian evidence synthesis of all available relevant surveillance data in England to estimate severity of the pandemic. Data sources All available surveillance systems relevant to the pandemic 2009 A/H1N1 influenza outbreak in England from June 2009 to February 2010. Pre-existing influenza surveillance systems, including estimated numbers of symptomatic cases based on consultations to the health service for influenza-like illness and cross sectional population serological surveys, as well as systems set up in response to the pandemic, including follow-up of laboratory confirmed cases up to end of June 2009 (FF100 and Fluzone databases), retrospective and prospective follow-up of confirmed hospitalised cases, and reported deaths associated with pandemic 2009 A/H1N1 influenza. Main outcome measures Age specific and wave specific probabilities of infection and symptomatic infection resulting in hospitalisation, intensive care admission, and death, as well as infection attack rates (both symptomatic and total). The probabilities of intensive care admission and death given hospitalisation over time are also estimated to evaluate potential changes in severity across waves. Results In the summer wave of A/H1N1 influenza, 0.54% (95% credible interval 0.33% to 0.82%) of the estimated 606 100 (419 300 to 886 300) symptomatic cases were hospitalised, 0.05% (0.03% to 0.08%) entered intensive care, and 0.015% (0.010% to 0.022%) died. These correspond to 3200 (2300 to 4700) hospital admissions, 310 (200 to 480) intensive care admissions, and 90 (80 to 110) deaths in the summer wave. In the second wave, 0.55% (0.28% to 0.89%) of the 1 352 000 (829 900 to 2 806 000) estimated symptomatic cases were hospitalised, 0.10% (0.05% to 0.16%) were admitted to intensive care, and 0.025% (0.013% to 0.040%) died. These correspond to 7500 (5900 to 9700) hospitalisations, 1340 (1030 to 1790) admissions to intensive care, and 240 (310 to 380) deaths. Just over a third (35% (26% to 45%)) of infections were estimated to be symptomatic. The estimated probabilities of infections resulting in severe events were therefore 0.19% (0.12% to 0.29%), 0.02% (0.01% to 0.03%), and 0.005% (0.004% to 0.008%) in the summer wave for hospitalisation, intensive care admission, and death respectively. The corresponding second wave probabilities are 0.19% (0.10% to 0.32%), 0.03% (0.02% to 0.06%), and 0.009% (0.004% to 0.014%). An estimated 30% (20% to 43%) of hospitalisations were detected in surveillance systems in the summer, compared with 20% (15% to 25%) in the second wave. Across the two waves, a mid-estimate of 11.2% (7.4% to 18.9%) of the population of England were infected, rising to 29.5% (16.9% to 64.1%) in 5-14 year olds. Sensitivity analyses to the evidence included suggest this infection attack rate could be as low as 5.9% (4.2% to 8.7%) or as high as 28.4% (26.0% to 30.8%). In terms of the probability that an infection leads to death in the second wave, these correspond, respectively, to a high estimate of 0.017% (0.011% to 0.024%) and a low estimate of 0.0027% (0.0024% to 0.0031%). Conclusions This study suggests a mild pandemic, characterised by case and infection severity ratios increasing between waves. Results suggest low ascertainment rates, highlighting the importance of systems enabling early robust estimation of severity, to inform optimal public health responses, particularly in light of the apparent resurgence of the 2009 A/H1N1 strain in the 2010-11 influenza season.

[1]  Simon Cauchemez,et al.  Assessing the severity of the novel influenza A/H1N1 pandemic , 2009, BMJ : British Medical Journal.

[2]  J. Oxford,et al.  Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. , 2001, JAMA.

[3]  A. Charlett,et al.  Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  N Wilson,et al.  The emerging influenza pandemic: estimating the case fatality ratio. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  Benjamin J Cowling,et al.  The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Marc Lipsitch,et al.  Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009 , 2009, Emerging infectious diseases.

[7]  N. Ferguson,et al.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies. , 2008, American journal of epidemiology.

[8]  K Mason,et al.  Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  Simon Cauchemez,et al.  Managing and reducing uncertainty in an emerging influenza pandemic. , 2009, The New England journal of medicine.

[10]  Cecile Viboud,et al.  The signature features of influenza pandemics--implications for policy. , 2009, The New England journal of medicine.

[11]  Paul J. Birrell,et al.  Bayesian modeling to unmask and predict influenza A/H1N1pdm dynamics in London , 2011, Proceedings of the National Academy of Sciences.

[12]  M. Lipsitch,et al.  The severity of pandemic H1N1 influenza in the United States, April - July 2009. , 2009, PLoS currents.

[13]  Katharine H. McVeigh,et al.  Case Fatality Rates Based on Population Estimates of Influenza-Like Illness Due to Novel H1N1 Influenza: New York City, May–June 2009 , 2010, PloS one.

[14]  L. Donaldson,et al.  Hospitalization in two waves of pandemic influenza A(H1N1) in England , 2010, Epidemiology and Infection.

[15]  A. Charlett,et al.  Has estimation of numbers of cases of pandemic influenza H1N1 in England in 2009 provided a useful measure of the occurrence of disease? , 2011, Influenza and other respiratory viruses.

[16]  R. Pebody,et al.  Epidemiological report of pandemic (H1N1) 2009 in the UK, April 2009 - May 2010. , 2010 .

[17]  Benjamin J Cowling,et al.  Comparative epidemiology of pandemic and seasonal influenza A in households. , 2010, The New England journal of medicine.

[18]  Oliver T Mytton,et al.  Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study , 2009, BMJ : British Medical Journal.

[19]  Andrew Thomas,et al.  The BUGS project: Evolution, critique and future directions , 2009, Statistics in medicine.

[20]  S. Bird Like-with-like comparisons? , 2010, The Lancet.

[21]  A. Schuchat,et al.  Seasonal Patterns of Invasive Pneumococcal Disease , 2003, Emerging infectious diseases.

[22]  M. Baguelin,et al.  Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. , 2010, Health technology assessment.

[23]  N. Andrews,et al.  Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study , 2010, The Lancet.

[24]  M. van Boven,et al.  Optimizing infectious disease interventions during an emerging epidemic , 2009, Proceedings of the National Academy of Sciences.

[25]  Hiroshi Nishiura,et al.  Early Epidemiological Assessment of the Virulence of Emerging Infectious Diseases: A Case Study of an Influenza Pandemic , 2009, PloS one.